195 related articles for article (PubMed ID: 16879014)
1. Chronic idiopathic myelofibrosis: clinicopathologic features, pathogenesis, and prognosis.
Ahmed A; Chang CC
Arch Pathol Lab Med; 2006 Aug; 130(8):1133-43. PubMed ID: 16879014
[TBL] [Abstract][Full Text] [Related]
2. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
3. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
4. Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status.
Bock O; Neuse J; Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H
Am J Pathol; 2006 Aug; 169(2):471-81. PubMed ID: 16877349
[TBL] [Abstract][Full Text] [Related]
5. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.
Rudzki Z; Sacha T; Stój A; Czekalska S; Wójcik M; Skotnicki AB; Grabowska B; Zduńczyk A; Okoń K; Stachura J
Int J Hematol; 2007 Aug; 86(2):130-6. PubMed ID: 17875526
[TBL] [Abstract][Full Text] [Related]
6. Polycythemia vera: new clinicopathologic perspectives.
Cao M; Olsen RJ; Zu Y
Arch Pathol Lab Med; 2006 Aug; 130(8):1126-32. PubMed ID: 16879013
[TBL] [Abstract][Full Text] [Related]
7. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
[TBL] [Abstract][Full Text] [Related]
8. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
9. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.
Wernig G; Mercher T; Okabe R; Levine RL; Lee BH; Gilliland DG
Blood; 2006 Jun; 107(11):4274-81. PubMed ID: 16478879
[TBL] [Abstract][Full Text] [Related]
10. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology.
Gianelli U; Vener C; Raviele PR; Moro A; Savi F; Annaloro C; Somalvico F; Radaelli F; Franco V; Deliliers GL
Leuk Lymphoma; 2006 Sep; 47(9):1774-81. PubMed ID: 17064987
[TBL] [Abstract][Full Text] [Related]
11. Chronic idiopathic myelofibrosis terminating in extramedullary anaplastic plasmacytoma.
Liu ML; Kallakury B; Kessler C; Hartmann DP; Azumi N; Ozdemirli M
Leuk Lymphoma; 2006 Feb; 47(2):315-22. PubMed ID: 16321864
[TBL] [Abstract][Full Text] [Related]
12. Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining.
Ponzoni M; Savage DG; Ferreri AJ; Pruneri G; Viale G; Servida P; Bertolini F; Orazi A
Mod Pathol; 2004 Dec; 17(12):1513-20. PubMed ID: 15272276
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis.
Vener C; Fracchiolla NS; Gianelli U; Calori R; Radaelli F; Iurlo A; Caberlon S; Gerli G; Boiocchi L; Deliliers GL
Blood; 2008 Feb; 111(4):1862-5. PubMed ID: 18029552
[TBL] [Abstract][Full Text] [Related]
14. Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis.
Thiele J; Kvasnicka HM
Ann Hematol; 2006 Apr; 85(4):226-32. PubMed ID: 16421727
[TBL] [Abstract][Full Text] [Related]
15. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
16. Hematopathologic findings in chronic idiopathic myelofibrosis.
Thiele J; Kvasnicka HM
Semin Oncol; 2005 Aug; 32(4):380-94. PubMed ID: 16202684
[TBL] [Abstract][Full Text] [Related]
17. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
18. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
19. [The development of myelofibrosis in prefibrotic cIMF. An investigation of the progression by sequential bone marrow biopsies in 38 patients].
Buhr T; Länger F; Kreft A; Büsche G; Choritz H; Kreipe H
Pathologe; 2002 Nov; 23(6):433-7. PubMed ID: 12436296
[TBL] [Abstract][Full Text] [Related]
20. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
